10.15131/shef.data.11890008.v1
Rachid Rafia
Rachid
Rafia
Diana Papaioannou
Diana
Papaioannou
Matthew Stevenson
Matthew
Stevenson
J. Rathbone
J.
Rathbone
Helen Buckley Woods
Helen Buckley
Woods
Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK
The University of Sheffield
2020
cost-effectiveness
rituximab
chemotherapy
Follicular lymphoma
United Kingdom
UK
health economics
Non-Hodgkin’s lymphoma
NHLS
Health Economics
Health Care
2020-02-25 10:35:17
Poster
https://orda.shef.ac.uk/articles/poster/Evaluating_the_cost-effectiveness_of_the_addition_of_rituximab_to_chemotherapy_in_the_first-line_treatment_of_Follicular_Lymphoma_patients_in_the_UK/11890008
INTRODUCTION
Follicular lymphoma (FL), a clinical subtype of Non-Hodgkin’s lymphoma (NHL) , develops
slowly and often without symptoms for many years. In 2008, the incidence of FL in England
and Wales was 3.4 per 100,000 persons. Over 70% of FLs are diagnosed in persons aged
over 60 years, and 85-90% present with advanced disease, which is defined as lymph nodes
on both sides of the diaphragm being involved (stage III) or disease is disseminated with one
or more extra-lymphatic organs involved (stage IV). Advanced FL is not curable, thus the aim
of disease management is to both increase patient life expectancy and to increase patient
health-related quality of life. The objective of this study is to assess, from a UK NHS
perspective, the cost-effectiveness of the addition of rituximab (R) to selected
chemotherapies: CVP (cyclophosphamide, vincristine and prednisolone); CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisolone) and MCP (mitoxantrone,
chlorambucil and prednisolone) in the first-line treatment of follicular lymphoma.